- Home
- Publications
- Publication Search
- Publication Details
Title
Immune therapy of melanoma: Overview of therapeutic vaccines
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-02-01
DOI
10.1002/jcp.28181
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Involvement of CD24 in Multiple Cancer Related Pathways Makes It an Interesting New Target for Cancer Therapy
- (2018) Shirin Eyvazi et al. CURRENT CANCER DRUG TARGETS
- Antibody based EpCAM targeted Therapy of Cancer, Review and update
- (2018) Shirin Eyvazi et al. CURRENT CANCER DRUG TARGETS
- Anti-CD37 targeted immunotherapy of B-Cell malignancies
- (2018) Zahra Payandeh et al. BIOTECHNOLOGY LETTERS
- Overview of CD24 as a new molecular marker in ovarian cancer
- (2018) Vahideh Tarhriz et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Identification of a novel single chain fragment variable antibody targeting CD24-expressing cancer cells
- (2017) Shirin Eyvazi et al. IMMUNOLOGY LETTERS
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
- (2017) Krzysztof M. Zak et al. STRUCTURE
- Current status and perspectives in immunotherapy for metastatic melanoma
- (2017) Riccardo Marconcini et al. Oncotarget
- Liposome-mediated RNA interference delivery against Erk1 and Erk2 does not equally promote chemosensitivity in human hepatocellular carcinoma cell line HepG2
- (2017) Amir Mehdizadeh et al. Artificial Cells Nanomedicine and Biotechnology
- A phase I clinical trial on the combined intravenous (IV) and intradermal (ID) administration of autologous TriMix-DC cellular therapy in patients with pretreated melanoma (TriMixIDIV).
- (2017) B. Neyns et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab: A Review in Advanced Melanoma
- (2016) Emma D. Deeks DRUGS
- Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
- (2016) Sofie Wilgenhof et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- Nivolumab in NSCLC: latest evidence and clinical potential
- (2015) Raghav Sundar et al. Therapeutic Advances in Medical Oncology
- Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination
- (2015) Kalijn F Bol et al. OncoImmunology
- Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases
- (2014) Sofie Wilgenhof et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Pembrolizumab: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review)
- (2014) SADEK MALAS et al. ONCOLOGY REPORTS
- PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
- (2014) Jason Madore et al. Pigment Cell & Melanoma Research
- A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients
- (2013) S. Wilgenhof et al. ANNALS OF ONCOLOGY
- Historical review of melanoma treatment and outcomes
- (2013) Carrie Lee et al. CLINICS IN DERMATOLOGY
- Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?
- (2013) Robert O Dillman et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation
- (2013) D V Chan et al. GENES AND IMMUNITY
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Skin melanocytes: biology and development
- (2013) Mirosława Cichorek et al. Postepy Dermatologii i Alergologii
- Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma
- (2013) Jianda Yuan et al. Journal for ImmunoTherapy of Cancer
- The Role of the PI3K-AKT Pathway in Melanoma
- (2012) Michael A. Davies CANCER JOURNAL
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Tumor Stem Cell Antigens as Consolidative Active Specific Immunotherapy
- (2012) Robert O. Dillman et al. JOURNAL OF IMMUNOTHERAPY
- Carcinogenic risks of Psoralen UV-A therapy and Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review
- (2012) E. Archier et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma
- (2011) Sofie Wilgenhof et al. JOURNAL OF IMMUNOTHERAPY
- Redirected Lysis of Human Melanoma Cells by a MCSP/CD3-bispecific BiTE Antibody That Engages Patient-derived T Cells
- (2011) Hitoe Torisu-Itakura et al. JOURNAL OF IMMUNOTHERAPY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanocortin 1 Receptor Variants: Functional Role and Pigmentary Associations
- (2011) Clio Dessinioti et al. PHOTOCHEMISTRY AND PHOTOBIOLOGY
- CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma
- (2011) Matthew A. Price et al. Pigment Cell & Melanoma Research
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
- (2011) O. S. Qureshi et al. SCIENCE
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
- (2010) Ryosuke Hino et al. CANCER
- Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
- (2010) J. F. M. Jacobs et al. CLINICAL CANCER RESEARCH
- CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
- (2010) Xinhui Wang et al. JNCI-Journal of the National Cancer Institute
- Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
- (2010) Marco de Bruyn et al. Molecular Cancer
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic antibodies: successes, limitations and hopes for the future
- (2009) Patrick Chames et al. BRITISH JOURNAL OF PHARMACOLOGY
- Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients
- (2009) A. Bonehill et al. CLINICAL CANCER RESEARCH
- Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
- (2009) B. Li et al. CLINICAL CANCER RESEARCH
- Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA
- (2008) Aude Bonehill et al. MOLECULAR THERAPY
- Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)
- (2008) J. Weber ONCOLOGIST
- Phase- and Stage-Related Proportions of T Cells Bearing the Transcription Factor FOXP3 Infiltrate Primary Melanoma
- (2007) Giuseppe De Panfilis et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now